Overview

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, prospective, randomized controlled clinical study comparing the efficacy and safety of CLAG+VEN and CLAG regimens in relapsed/refractory(r/r) AML.
Phase:
PHASE4
Details
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborators:
Affiliated Hospital of Guangdong Medical University
Central People's Hospital of Zhanjiang
Dongguan People's Hospital
First Affiliated Hospital of Guangxi Medical University
First People's Hospital of Foshan
Foresea Life Insurance Guangzhou General Hospital
Guangdong Second Provincial General Hospital
Guangzhou First People's Hospital
Guangzhou General Hospital of Guangzhou Military Command
Guangzhou No.12 People's Hospital
Guangzhou Panyu Central Hospital
Guilin Medical University, China
Hainan General Hospital
Huizhou Municipal Central Hospital
Jiangmen Central Hospital
LiuZhou People's Hospital
Maoming People's Hospital
Peking University Shenzhen Hospital
Second Affiliated Hospital of Guangzhou Medical University
Shantou Central Hospital
Shenzhen Hospital of Southern Medical University
Shenzhen Second People's Hospital
Southern Medical University, China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tungwah Hospital of Sun Yat-Sen University
Yuebei People's Hospital
Zhongshan People's Hospital, Guangdong, China
ZhuHai Hospital
Treatments:
Cladribine
Cytarabine
Filgrastim
Granulocyte Colony-Stimulating Factor
venetoclax